Core Viewpoint - New Earth Resources Corp. has entered into a service agreement with APEX Geoscience Ltd. to enhance its exploration and evaluation activities in mineral exploration, particularly focusing on critical and strategic minerals [1][2][3] Group 1: Service Agreement Details - APEX Geoscience Ltd. will provide independent geological consulting and technical services to support New Earth's exploration activities on an as-needed basis, including geological data review, technical report authoring, and project guidance [2] - The engagement of APEX is expected to enhance New Earth's technical capabilities and strengthen its decision-making in exploration [3] Group 2: Company Overview - New Earth Resources Corp. is a Canadian mineral exploration company focused on acquiring and developing advanced and early-stage exploration projects, with its flagship project being the 100% owned Lucky Boy Uranium Property in Arizona, USA, which spans approximately 273 acres [4] - The company also has options to acquire interests in additional projects, including the SL Project in Quebec, covering approximately 1,102 hectares, and the Red Wine Rare Earth Project in Labrador, covering approximately 1,575 hectares [5]

Core Viewpoint - Trifork Group AG has initiated a share buyback program aimed at repurchasing shares worth up to DKK 14.92 million (approximately EUR 2 million) from 23 December 2025 to 26 February 2026 [1][2]. Group 1: Share Buyback Program Details - The share buyback program is in accordance with Regulation No. 596/2014 and runs until 26 February 2026 [1]. - As of the latest report, Trifork has repurchased a total of 76,647 shares for a total amount of DKK 7,074,671 [3]. - Prior to the buyback, Trifork held 219,735 treasury shares, which represented 1.1% of the share capital [2]. Group 2: Transaction Overview - The average purchase price of the shares repurchased under the program is DKK 92.30 [2]. - The daily transactions include purchases on specific dates with varying numbers of shares and transaction values, such as 4,700 shares at an average price of DKK 90.68 on 19 January 2026 [2]. - After the buyback, Trifork now holds a total of 262,795 treasury shares, which corresponds to 1.3% of the total registered shares of 19,744,899 [3]. Group 3: Company Background - Trifork is a global technology company specializing in innovative digital products and solutions for enterprise and public sector customers [4]. - The company employs 1,197 people across 16 countries and focuses on advanced software in various sectors including public administration, healthcare, and financial services [4]. - Trifork Labs, the R&D arm of the company, is dedicated to driving innovation by investing in high-potential technology companies [4].

Core Viewpoint - SYNERGIE Group has signed an agreement to acquire a majority stake in Agilus Work Solutions, marking a significant step in its expansion strategy in the Canadian market [1][5] Group 1: Acquisition Details - The acquisition is subject to clearance by the Canadian Competition Bureau and does not result in an immediate transfer of control [1] - This transaction is the largest international acquisition for SYNERGIE to date, reinforcing its commitment to providing world-class HR solutions [1] Group 2: Market Opportunity - The Canadian recruitment and HR solutions market is characterized by structural labor shortages and diversified demand across key sectors, presenting a strategic opportunity for growth [2] - The growing adoption of outsourced and technology-enabled HR services supports resilient growth and long-term value creation in the market [2] Group 3: Agilus Work Solutions Overview - Founded in 1976, Agilus is the 8th largest staffing player in Canada, with a nationwide network of 14 branches [3] - In 2025, Agilus is expected to generate approximately CAD 300 million in revenues (around €190 million), reflecting its scale and market momentum [3] Group 4: Strategic Benefits of the Acquisition - The combination of SYNERGIE and Agilus networks will provide extensive national coverage across Canada and create significant value through complementary market positions, especially in engineering, IT, and professional skill sets [4] - This acquisition aims to accelerate SYNERGIE's development in Canada and achieve critical scale in the North American market [5] Group 5: Future Outlook - The transaction enhances SYNERGIE's capacity to support clients in their international growth, leveraging a full suite of global human resources solutions across 17 countries [6] - Upcoming communication of 2025 revenue is scheduled for January 28, 2026, after market close [6]

Group 1 - The share repurchase programme of Jyske Bank is set to run from 26 February 2025 to 30 January 2026, with a total value of up to DKK 2.25 billion [1] - As of the latest announcement, Jyske Bank has accumulated 3,263,646 shares under the programme, representing 5.31% of the share capital [2] - The average purchase price of shares acquired under the programme is DKK 676.38, with a total transaction value of DKK 2,207,451,574 [2] Group 2 - The share repurchase programme is structured in compliance with the EU Market Abuse Regulation and the Safe Harbour Rules [1] - Recent transactions include purchases on 19 January 2026 to 23 January 2026, with average prices ranging from DKK 918.65 to DKK 940.42 [2] - The total number of shares acquired in the recent transactions amounts to 65,392 shares [2]

Core Insights - Scancell Holdings plc has received FDA clearance for its Investigational New Drug application for a Phase 3 trial of iSCIB1+ Immunobody® in advanced melanoma, with progression-free survival as the primary endpoint [1][3] - The Phase 2 SCOPE trial demonstrated a 24% improvement in progression-free survival (PFS) for iSCIB1+ compared to the standard of care and historical controls [1][4] - The SCOPE trial involved 140 patients and evaluated the efficacy of iSCIB1+ in combination with nivolumab and ipilimumab for previously untreated unresectable stage IIIB/IV melanoma [2][5] Company Developments - Scancell has identified a selection marker to enrich the Phase 3 trial for responders, focusing on patients with specific human leukocyte antigen (HLA) alleles, which represent 80% of melanoma patients [3] - Updated data from the SCOPE trial show that PFS for the target population was 74% at 16 months, significantly higher than the 50% PFS reported for the current standard of care (ipilimumab plus nivolumab) at 11.5 months [4] - The company is exploring various financing options, including potential partnerships, to support the Phase 3 trial [3] Product Pipeline - iSCIB1+ is part of Scancell's DNA ImmunoBody® platform, which aims to generate safe and long-lasting tumor-specific immunity [6] - The company is also developing Modi-1, a peptide immunotherapy from its Moditope® platform, currently in a Phase 2 study for a range of solid tumors [6] - Scancell's subsidiary, GlyMab Therapeutics Ltd., is focused on developing high-affinity GlyMab® antibodies targeting tumor-specific glycans [6]

Core Insights - Egide Group reported consolidated revenue of €31.34 million for 2025, marking a 4% increase from €30.01 million in 2024, driven by growth in high-tech activities, particularly in thermal imaging applications [2][6][14]. Financial Performance - The thermal imaging segment saw significant growth of 56%, with revenue rising from €9.08 million in 2024 to €14.19 million in 2025, now accounting for 45% of total revenue [19][21]. - Egide SA's revenue grew by 12% to €16.50 million, while Egide USA's revenue increased by 29% to €10.75 million [13][16]. - Santier's revenue, however, declined by 41% to €4.09 million due to the discontinuation of certain high-value programs [17]. Strategic Initiatives - The company focused on a value-creating repositioning strategy in 2025, emphasizing technology-intensive segments and optimizing its product mix to favor higher-margin products [9][11]. - Efforts to diversify the customer portfolio were successful, with a notable increase in European activities, which grew by 30% [6][10]. - The governance structure was strengthened with the appointment of Ignace Dupon as CEO, who aims to enhance operational synergies between French and US operations [5][7]. Market Dynamics - Europe emerged as the primary growth driver, benefiting from renewed orders from long-standing customers, particularly in the thermal imaging segment [25]. - The US market showed positive growth from Egide USA, which helped offset declines from Santier, indicating effective portfolio management across different regions [26]. Future Outlook - For 2026, the company plans to continue diversifying its customer base and product offerings, focusing on key defense and aerospace technologies to improve operational efficiency [27].

Core Viewpoint - TGS, a leading global provider of energy data and intelligence, is set to release its Q4 2025 results on February 12, 2026, at 07:00 a.m. CET, with a public presentation following at 09:00 a.m. CET [1] Group 1 - The Q4 2025 earnings release and presentation will be accessible on TGS's official website and news platforms [2] - CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at Thon Hotel Vika Atrium in Oslo, Norway [1] - The presentation will be webcasted live, allowing broader access for stakeholders [1] Group 2 - TGS specializes in providing advanced data and intelligence to the energy sector, supporting exploration and production activities [3] - The company utilizes cutting-edge technology and a diverse energy data library to assist clients in making informed decisions [3] - TGS is recognized as a trusted partner in the global energy market, offering a comprehensive range of insights across the energy value chain [3]

Core Insights - EP Group, controlled by Daniel Křetínský, has proposed a public tender offer for the outstanding shares and OCEANEs of Fnac Darty [2] - The retail sector in France is facing significant challenges, with a decline in activity observed in December, particularly in stores, but Fnac Darty has managed to outperform the market due to its omnichannel and service-oriented strategy [3] - The Group's revenue for 2025 is projected to be stable at €10,330 million, with a slight increase in current operating income expected to reach €203.1 million [5][9] Financial Performance - The estimated revenue for 2025 is expected to show a +0.7% increase year-on-year, with France contributing +0.5% and the rest of Europe +1.1% [10] - The current operating margin is anticipated to reach 2.0% by the end of December 2025, reflecting an increase of approximately 5 basis points [6][10] - Free Cash Flow is projected to be around €145 million, consistent with 2024 figures excluding asset disposals [6][9] Strategic Developments - The Group is actively seeking a partner for Nature & Découvertes to better support its development, with a reclassification in financial statements as of December 31, 2025, in accordance with IFRS 5 [4][9] - The strategic roadmap, known as the Beyond everyday plan, is being implemented with confidence, and objectives for 2030 have been reaffirmed [7] - The audited annual results for 2025 are scheduled to be published on February 25, 2026, after market close [7][13]

Core Viewpoint - Sampo plc has initiated a share buyback program, acquiring a total of 366,648 A shares on 23 January 2026, as part of a broader plan to repurchase shares worth up to EUR 150 million, which began on 6 November 2025 [1][2]. Group 1: Share Buyback Details - On 23 January 2026, Sampo plc acquired 366,648 A shares at a daily weighted average price of EUR 9.52 [1]. - The buyback occurred across multiple markets, with the highest daily volume recorded on the XHEL market at 170,479 shares [1]. - The share buyback program is compliant with the Market Abuse Regulation (EU) 596/2014 and was authorized by Sampo's Annual General Meeting on 23 April 2025 [1]. Group 2: Ownership and Transactions - Following the buyback transactions, Sampo plc now owns a total of 13,804,419 A shares, which represents 0.52% of the total number of shares in the company [2]. - Detailed information regarding each transaction is available in the appendix of the announcement [2].

Group 1 - AMG Critical Materials N.V. announced that its subsidiary, AMG LIVA, will install the Hybrid Energy Storage System at Aramco's Bulk Plant in Tabuk, Saudi Arabia, integrating it with an existing solar plant [1] - The Hybrid ESS combines Lithium-Ion and Vanadium Redox Flow batteries with AI routines to enhance efficiency, safety, reliability, and battery lifespan [1] - This initiative supports Saudi Arabia's 2030 Vision by reducing carbon emissions, increasing renewable energy deployment, and enhancing energy storage capabilities [2] Group 2 - The project complements the IK Metals Reclamation and Catalyst Manufacturing Project, known as the IK Supercenter, which focuses on recycling metals, including vanadium concentrate from spent catalysts [3] - The IK Supercenter is a joint venture between Shell & AMG Recycling B.V. and local partner United Company for Industry (UCI), aiming to reduce carbon emissions compared to traditional mining processes [3] - The facility will include a vanadium electrolyte production plant to support the Kingdom's vanadium flow battery market, creating a fully integrated value chain in Saudi Arabia [3] Group 3 - AMG's mission is to provide critical materials and technologies to promote a less carbon-intensive world, focusing on energy storage materials like lithium and vanadium [4] - The company is a market leader in recycling vanadium from oil refining residues and operates in advanced metallurgy, serving various sectors including aerospace [5] - AMG has approximately 3,600 employees and operates globally with production facilities in multiple countries, including Germany, the UK, and the US [6]